Solute carrier membrane transporters: emerging targets in CNS disorders.
Dysregulated solute carrier (SLC) transporters are emerging as promising therapeutic targets for CNS disorders, with many linked to epilepsy, neurodegeneration, and autism.
- Why it matters: Understanding and targeting SLC transporters is crucial because they regulate key metabolites and ions that influence brain development and disease, yet many remain poorly characterized.
- What they did: The study reviews recent progress in identifying the functions of previously uncharacterized SLCs and developing chemical strategies to modulate their activity, highlighting their therapeutic potential.
- The result: Advances in SLC biology are broadening the scope of CNS drug discovery, enabling new treatments for neurological disorders by precisely targeting transporter regulation.